What should dermatologists know about osteoporosis?

Justyna Sałata-Nowak; Iwona Flisiak; Bożena Chodynicka

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2010
vol. 97

Send email

Copy url:

abstract:

Review paper

What should dermatologists know about osteoporosis?

Justyna Sałata-Nowak

,

Iwona Flisiak

,

Bożena Chodynicka

Przegl Dermatol 2010, 97, 212–218

Online publish date: 2010/07/01

View full text Get citation

Prolonged glucocorticosteroid therapy is the most common cause of secondary osteoporosis, named glucocorticoid-induced osteoporosis. It is estimated that 30 to 50% of chronic glucocorticosteroid users experience vertebral or hip fractures. Prevention of osteoporosis is a very important public health concern. Dermatologists are among the leading prescribers of oral glucocorticosteroids; therefore, this topic is of utmost importance. Dermatological patients treated with glucocorticosteroids for longer than 3 months should receive prophylactic treatment to decrease the risk of bone loss. When glucocorticoids are used for a period shorter than 3 months, current literature does not suggest prophylaxis. All patients starting glucocorticosteroid treatment should be given instructions on general measures for prevention of bone loss.

keywords:

What should dermatologists know about osteoporosis?

Justyna Sałata-Nowak , Iwona Flisiak , Bożena Chodynicka

glucocorticoid-induced osteoporosis, glucocorticoids, prevention

Justyna Sałata-Nowak

,

Iwona Flisiak

,

Bożena Chodynicka